Shahid Aziz, MD
Endocrinology, Diabetes & Metabolism · San Antonio, TXNPI 1063611697
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Corcept Therapeutics at 28.1% of the total. Reporting peaked in 2022 at $38,528 and has fallen 66.2% since, to $13,018 in 2025. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,434 payments — averaging $120.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$49K
- Novo Nordisk$36K
- Intuity Medical Inc$20K
- Cequr Corporation$11K
- Sanofi-aventis U.S. LLC$11K
- Lilly USA, LLC$9K
- plus $37K from 54 others
What the payments were for
- Consulting fees$26,55015%
- Speaking & faculty fees$102,62259%
- Travel & lodging$13,7508%
- Food & beverage$30,30217%
- Education$1940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$46,619
- Wegovy$26,048
- Pogo Automatic Blood Glucose Monitoring System$19,490
- JARDIANCE$11,544
- CeQur Simplicity$11,461
- SOLIQUA 100/33$8,269
- Saxenda$6,176
- AFREZZA$3,812
- TOUJEO$3,676
- DEXCOM CGM$3,315
- V-GO$2,400
- V-GO DISPOSABLE INSULIN DELIVERY$1,906
- Tirosint$1,250
- FARXIGA$848
- iLet Bionic Pancreas$744
- t:slim X2 Insulin Pump with Control-IQ$685
- Tirosint-SOL$500
- Ozempic$487
- DEXCOM G6 TRANSMITTER$454
- MOUNJARO$239
How this compares
$173,417 in reported general payments places this provider in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 614 | $745,031 |
| MounjaroTirzepatide | 410 | $469,534 |
| JardianceEmpagliflozin | 199 | $180,494 |
| Tresiba Flextouch U-200Insulin Degludec | 194 | $160,942 |
| TrulicityDulaglutide | 110 | $136,479 |
| FarxigaDapagliflozin Propanediol | 167 | $130,543 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 45 | $99,277 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 87 | $79,134 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 66 | $77,217 |
| ProliaDenosumab | 45 | $74,810 |
| RybelsusSemaglutide | 48 | $67,174 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 100 | $62,626 |
| Teriparatide | 15 | $50,881 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 60 | $47,309 |
| Xigduo XrDapaglifloz Propaned/Metformin | 40 | $40,437 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $35,973 | $829,709715 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $9,098 | $623,254573 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy | $5,493 | $291,495329 claims |
| AstraZenecaFarxiga | $2,625 | $130,543167 claims |
| AmgenProlia | $1,884 | $74,81045 claims |
| MerckJanumet Xr, Januvia | $161 | $35,80632 claims |
| Radius Health, Inc.Tymlos | $270 | $32,86813 claims |
| Mannkind CorporationAfrezza | $5,084 | $29,42827 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $10,663 | $12,38313 claims |
| Cequr CorporationCequr Simplicity | $11,461 | $10,79524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in San Antonio
- Ralph DefronzoSan Antonio$880K
- Firas AkhrassSan Antonio$801K
- Carolina Solis-HerreraSan Antonio$600K
- Jeannie BaqueroSan Antonio$573K
- Kathleen HandsSan Antonio$223K
- William TrigosoSan Antonio$170K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.